Racial differences in percent of men with advanced prostate cancer prescribed targeted agents following initiation of in-office pharmacies by single specialty urology practices

You have accessJournal of UrologyCME1 Apr 2023MP29-04 RACIAL DIFFERENCES IN PERCENT OF MEN WITH ADVANCED PROSTATE CANCER PRESCRIBED TARGETED AGENTS FOLLOWING INITIATION OF IN-OFFICE PHARMACIES BY SINGLE SPECIALTY UROLOGY PRACTICES Dawson Hill, Samuel Kaufman, Megan Caram, Vahakn Shahinian, Brent Hollenbeck, and Avinash Maganty Dawson HillDawson Hill More articles by this author , Samuel KaufmanSamuel Kaufman More articles by this author , Megan CaramMegan Caram More articles by this author , Vahakn ShahinianVahakn Shahinian More articles by this author , Brent HollenbeckBrent Hollenbeck More articles by this author , and Avinash MagantyAvinash Maganty More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000003257.04AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Recent advances in the delivery of care for advanced prostate cancer include provision of novel targeted agents directly to patients through in-office dispensing, which has resulted in an increase in the number of prescriptions for abiraterone and enzalutamide. However, the extent to which in-office dispensing may differentially impact black versus non-black men is unknown. METHODS: Single specialty urology practices with in-office dispensing initiated between 2014 and 2018 were identified using the National Council for Prescription Drug Programs. Matched control practices without in-office dispensing were also identified. Using a national 20% random sample of fee-for-service Medicare beneficiaries, men with advanced prostate cancer cared for by practices with and without in-office dispensing were identified. The primary outcome of interest was percent of men with advanced prostate cancer receiving prescriptions for abiraterone and enzalutamide over a five-year period (two years before and two years after the year in-office dispensing was initiated), stratified by race (black vs. non-black). RESULTS: A total of 2,444 men in dispensing practices and 1,453 men in practices without dispensing were identified, of whom 15% and 14% were black, respectively. Black men tended be younger, be of lower socioeconomic status, and have similar comorbidity scores compared to non-black patients. The percent of men receiving prescriptions for abiraterone and enzalutamide increased after initiation of in-office dispensing for both black (0% two years before to 11% two years after pharmacy opening) and non-black men (1% to 8%). The increase in prescriptions was less pronounced for practices without in-office dispensing for both black (2% to 6%) and non-black (2% to 6%) men. CONCLUSIONS: Following initiation of in-office dispensing among single specialty urology practices, a higher percent of both black and non-black men received targeted agents compared to those cared for by practices without in-office dispensing. Source of Funding: Avinash Maganty is supported by funding from the National Cancer Institute Ruth L. Kirschstein Postdoctoral Award F32 Grant F32CA275021-01 Brent K. Hollenbeck and Vahakn are supported by funding from a Research Scholar Grant from the American Cancer Society (RSGI-21-097-01-HOPS) and funding from the National Cancer Institute (R01CA269367-01). © 2023 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 209Issue Supplement 4April 2023Page: e381 Advertisement Copyright & Permissions© 2023 by American Urological Association Education and Research, Inc.MetricsAuthor Information Dawson Hill More articles by this author Samuel Kaufman More articles by this author Megan Caram More articles by this author Vahakn Shahinian More articles by this author Brent Hollenbeck More articles by this author Avinash Maganty More articles by this author Expand All Advertisement PDF downloadLoading ...